EAACI 2011 – a priority for Airsonett

Airsonett is one of EAACI’s Founder Sponsors since 2010, a long-term commitment which, among other things, signify a major investment in the yearly EAACI congress in Istanbul 11 – 15 June 2011. Airsonett will present new research data from the extensive multi-national 4A Study which was concluded in 2010.  The company will also be present with a stand where the congress delegates themselves can try Airsonett´s asthma treatment Protexo® . 

”The yearly EAACI congress for 2010 took place in London and Airsonett’s data from the 4A Study was elected the whole congress’ most interesting new research. We are naturally hoping for the same positive response and attention in Istanbul 2011.” says Dan Kristensson, CEO, Airsonett AB.

EAACI (European Academy of Allergy and Clinical Immunology) is an organization who attracts mainly European physicians with a special interest in allergy and asthma. EAACI organizes high quality congresses in Europe with focus on the scientific developments in the field of allergy and immunology.

“The EAACI congress is really becoming one of the absolutely strongest meetings for any allergy interested doctor or scientist, and is further developing on a yearly basis. The Founder Sponsors are important for the long term development of EAACI.” says Professor Jan Lötwall, EAACI President. “The EAACI congresses are continuously growing in the numbers of submitted and accepted abstracts, as well as attending delegates from all over the world.”

Airsonett is a research based medical technology company with a unique technology which leads the development of preventative and secondary preventative treatment of allergic asthma as well as management of airborne bacteria and virus contamination.

For more information, please contact:
Dan Kristensson, VD, Airsonett AB, tel. +46 431 402531, e-mail dan.kristensson@airsonett.com

For more information about EAACI, visit www.eaaci2011.com